• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

关于莫努匹拉韦作为一种有前景的治疗新冠肺炎口服药物的综述。

Review on molnupiravir as a promising oral drug for the treatment of COVID-19.

作者信息

Zarenezhad Elham, Marzi Mahrokh

机构信息

Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.

出版信息

Med Chem Res. 2022;31(2):232-243. doi: 10.1007/s00044-021-02841-3. Epub 2022 Jan 3.

DOI:10.1007/s00044-021-02841-3
PMID:35002192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8721938/
Abstract

During the COVID-19 pandemic, various drug candidates have been developed, molnupiravir (MK-4482 and EIDD-2801), which is a new orally anti-viral agent under development for the treatment of COVID-19, is under study in the final stage of the clinical trial. Molnupiravir enhances the replication of viral RNA mutations in animals and humans. Due to the high demand for the synthesis of this drug, it was essential to develop an efficient and suitable synthetic pathway from raw material. In this study, molecular docking analysis on molnupiravir is examined also, the mechanism of action (MOA) and the recent synthetic pathway is reported. This review will be helpful to different disciplines such as medicinal chemistry, organic chemistry, biochemistry, and pharmacology.

摘要

在新冠疫情期间，人们研发了多种候选药物，莫努匹韦（MK-4482和EIDD-2801）是一种正在研发的用于治疗新冠的新型口服抗病毒药物，正处于临床试验的最后阶段。莫努匹韦可增强动物和人类体内病毒RNA突变的复制。由于对这种药物的合成需求很高，因此从原材料开发一条高效且合适的合成途径至关重要。在本研究中，还对莫努匹韦进行了分子对接分析，报道了其作用机制（MOA）和最新的合成途径。这篇综述将对药物化学、有机化学、生物化学和药理学等不同学科有所帮助。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/9ea16cfcd69e/44_2021_2841_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/04f71f67a083/44_2021_2841_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/1703b5992b1f/44_2021_2841_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/02a85b08f64c/44_2021_2841_Sch1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/1444839ec088/44_2021_2841_Sch2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/b9b2ef5af27c/44_2021_2841_Sch3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/327e2e28b1dc/44_2021_2841_Sch4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/2421cf8e42c5/44_2021_2841_Sch5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/a393362d08bc/44_2021_2841_Sch6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/73adc63d53d1/44_2021_2841_Sch7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/df4b5dfda5e2/44_2021_2841_Sch8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/a906a82818f5/44_2021_2841_Sch9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/5d285f54e30e/44_2021_2841_Sch10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/9ea16cfcd69e/44_2021_2841_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/04f71f67a083/44_2021_2841_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/1703b5992b1f/44_2021_2841_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/02a85b08f64c/44_2021_2841_Sch1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/1444839ec088/44_2021_2841_Sch2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/b9b2ef5af27c/44_2021_2841_Sch3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/327e2e28b1dc/44_2021_2841_Sch4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/2421cf8e42c5/44_2021_2841_Sch5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/a393362d08bc/44_2021_2841_Sch6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/73adc63d53d1/44_2021_2841_Sch7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/df4b5dfda5e2/44_2021_2841_Sch8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/a906a82818f5/44_2021_2841_Sch9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/5d285f54e30e/44_2021_2841_Sch10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac21/8721938/9ea16cfcd69e/44_2021_2841_Fig3_HTML.jpg

相似文献

1
Review on molnupiravir as a promising oral drug for the treatment of COVID-19.关于莫努匹拉韦作为一种有前景的治疗新冠肺炎口服药物的综述。
Med Chem Res. 2022;31(2):232-243. doi: 10.1007/s00044-021-02841-3. Epub 2022 Jan 3.
2
The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review.恢复之药；莫努匹拉韦用于治疗新冠病毒肺炎患者；一项系统评价
Saudi Pharm J. 2022 May;30(5):508-518. doi: 10.1016/j.jsps.2022.03.002. Epub 2022 Mar 10.
3
Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.莫努匹拉韦对新型冠状病毒肺炎的抗病毒活性：证据的简要综述
Bull Natl Res Cent. 2022;46(1):62. doi: 10.1186/s42269-022-00753-9. Epub 2022 Mar 10.
4
Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine.从胞苷大规模合成莫努匹拉韦（MK-4482，EIDD-2801）的进展
ACS Omega. 2021 Apr 8;6(15):10396-10402. doi: 10.1021/acsomega.1c00772. eCollection 2021 Apr 20.
5
Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.莫努匹拉韦——一种新型口服抗SARS-CoV-2药物。
Antibiotics (Basel). 2021 Oct 23;10(11):1294. doi: 10.3390/antibiotics10111294.
6
Synthesis of molnupiravir (MK-4482, EIDD-2801): a promising oral drug for the treatment of COVID-19 starting from cytidine.莫努匹韦（MK-4482，EIDD-2801）的合成：一种从胞苷出发的治疗 COVID-19 的有前途的口服药物。
Nucleosides Nucleotides Nucleic Acids. 2023;42(6):427-435. doi: 10.1080/15257770.2022.2153140. Epub 2022 Dec 6.
7
Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19.工程化核糖基-1-激酶助力简明合成莫努匹拉韦，一种用于治疗新冠肺炎的抗病毒药物。
ACS Cent Sci. 2021 Dec 22;7(12):1980-1985. doi: 10.1021/acscentsci.1c00608. Epub 2021 Oct 29.
8
Scaling the Process Chemistry of a COVID-19 Antiviral Pharmaceutical Down for a Multistep Synthesis Experiment in the Undergraduate Teaching Laboratory.将一种新冠病毒抗病毒药物的工艺化学规模缩小，用于本科教学实验室的多步合成实验。
J Chem Educ. 2024 Feb 7;101(3):1211-1217. doi: 10.1021/acs.jchemed.3c00999. eCollection 2024 Mar 12.
9
Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial.莫努匹韦对奥密克戎变异株感染的抗病毒疗效和安全性：一项随机对照临床试验
Front Pharmacol. 2022 Jun 15;13:939573. doi: 10.3389/fphar.2022.939573. eCollection 2022.
10
Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment.疾病状态对大鼠中 EIDD-1931（莫那比拉韦的活性形式）口服药代动力学的影响及其在剂量调整中的意义。
Mol Pharm. 2023 Sep 4;20(9):4597-4610. doi: 10.1021/acs.molpharmaceut.3c00314. Epub 2023 Aug 1.

引用本文的文献

1
Small Molecule Drugs Targeting Viral Polymerases.靶向病毒聚合酶的小分子药物
Pharmaceuticals (Basel). 2024 May 20;17(5):661. doi: 10.3390/ph17050661.
2
Rapid development and mass production of SARS-CoV-2 neutralizing chicken egg yolk antibodies with protective efficacy in hamsters.快速开发和大量生产具有保护效力的 SARS-CoV-2 中和鸡卵黄抗体在仓鼠中。
Biol Res. 2024 May 6;57(1):24. doi: 10.1186/s40659-024-00508-y.
3
Recombinant ACE2 - Opportunities and Challenges in COVID-19 Treatment.重组血管紧张素转换酶2（ACE2）——新冠病毒肺炎治疗中的机遇与挑战

本文引用的文献

1
Toward a Practical, Nonenzymatic Process for Investigational COVID-19 Antiviral Molnupiravir from Cytidine: Supply-Centered Synthesis.从胞苷出发，迈向一种用于研究性COVID-19抗病毒药物莫努匹拉韦的实用非酶促工艺：以供应为中心的合成。
Org Process Res Dev. 2021 Dec 17;25(12):2679-2685. doi: 10.1021/acs.oprd.1c00219. Epub 2021 Dec 9.
2
Molnupiravir in COVID-19: A systematic review of literature.莫努匹韦治疗 COVID-19：文献系统评价。
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102329. doi: 10.1016/j.dsx.2021.102329. Epub 2021 Oct 30.
3
Molnupiravir: coding for catastrophe.
Infect Disord Drug Targets. 2025;25(1):e180424229061. doi: 10.2174/0118715265298816240321045741.
4
Antivirals for Broader Coverage against Human Coronaviruses.用于更广泛覆盖人类冠状病毒的抗病毒药物。
Viruses. 2024 Jan 20;16(1):156. doi: 10.3390/v16010156.
5
Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses.新型β-D-N4-羟基胞苷酯前药的合成及其抗病毒活性：作为治疗SARS-CoV-2和其他人类冠状病毒的潜在化合物
Pharmaceuticals (Basel). 2023 Dec 26;17(1):35. doi: 10.3390/ph17010035.
6
After the Hurricane: Anti-COVID-19 Drugs Development, Molecular Mechanisms of Action and Future Perspectives.飓风过后：抗 COVID-19 药物研发、作用机制和未来展望。
Int J Mol Sci. 2024 Jan 6;25(2):739. doi: 10.3390/ijms25020739.
7
What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms.有哪些当前的抗 COVID-19 药物？从传统到智能的分子机制。
Virol J. 2023 Oct 24;20(1):241. doi: 10.1186/s12985-023-02210-z.
8
An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations.抗新冠病毒药物莫努匹韦的一种活性代谢物在临床相关浓度下损害小鼠着床前胚胎。
Reprod Toxicol. 2023 Oct;121:108475. doi: 10.1016/j.reprotox.2023.108475. Epub 2023 Sep 23.
9
A sensitive UPLC-MS/MS method for the simultaneous assay and trace level genotoxic impurities quantification of SARS-CoV-2 inhibitor-Molnupiravir in its pure and formulation dosage forms using fractional factorial design.一种采用分数析因设计的超高效液相色谱-串联质谱法，用于同时测定新冠病毒抑制剂莫努匹韦原料药及其制剂剂型中的痕量遗传毒性杂质，并对其进行定量分析。
Results Chem. 2023 Dec;6:101019. doi: 10.1016/j.rechem.2023.101019. Epub 2023 Jun 27.
10
Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2.基于结构的 RdRp 抑制剂对 SARS-CoV-2 的药物设计。
Top Curr Chem (Cham). 2023 Jun 15;381(5):22. doi: 10.1007/s41061-023-00432-x.
莫努匹拉韦：引发灾难的编码。
Nat Struct Mol Biol. 2021 Sep;28(9):706-708. doi: 10.1038/s41594-021-00657-8.
4
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.莫努匹韦在 SARS-CoV-2 早期患者中的最佳剂量和安全性：一项 I 期、开放标签、剂量递增、随机对照研究。
J Antimicrob Chemother. 2021 Nov 12;76(12):3286-3295. doi: 10.1093/jac/dkab318.
5
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.莫努匹拉韦诱导的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）诱变机制。
Nat Struct Mol Biol. 2021 Sep;28(9):740-746. doi: 10.1038/s41594-021-00651-0. Epub 2021 Aug 11.
6
A Mini Review on Discovery and Synthesis of Remdesivir as an Effective and Promising Drug against COVID-19.关于瑞德西韦作为一种对抗新冠病毒的有效且有前景药物的发现与合成的综述
Russ J Bioorg Chem. 2021;47(3):609-621. doi: 10.1134/S1068162021030183. Epub 2021 Jun 11.
7
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.美国国立卫生研究院 SARS-CoV-2 抗病毒治疗峰会报告。
J Infect Dis. 2021 Jul 15;224(Supplement_1):S1-S21. doi: 10.1093/infdis/jiab305.
8
Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine.从胞苷大规模合成莫努匹拉韦（MK-4482，EIDD-2801）的进展
ACS Omega. 2021 Apr 8;6(15):10396-10402. doi: 10.1021/acsomega.1c00772. eCollection 2021 Apr 20.
9
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.莫努匹韦通过 RNA 模板促进 SARS-CoV-2 突变。
J Biol Chem. 2021 Jul;297(1):100770. doi: 10.1016/j.jbc.2021.100770. Epub 2021 May 11.
10
A High-Yielding Synthesis of EIDD-2801 from Uridine.由尿苷高产合成EIDD-2801。
European J Org Chem. 2020 Nov 22;2020(43):6736-6739. doi: 10.1002/ejoc.202001340. Epub 2020 Nov 12.